EN
  • FR
Contact
  • News
  • Media
  • Health professionals
  • CAREERS
LFB corp
  • The group
    • The LFB group
    • LFB Key dates
    • LFB worldwide
    • A special place in France
    • Governance
      • LFB SA Board of Directors
      • Group Executive Committee
      • LFB BIOMEDICAMENTS
      • LFB BIOTECHNOLOGIES
      • Composition and tasks of the Committees
    • The LFB in pictures
  • Products and activities
    • Medicinal products
    • LFB Research Grant in Immunology
    • Biosafety
  • Innovation
    • Products under development
    • Technology platforms
    • Improving biosafety
  • Responsibilities
    • Rare diseases
    • Relations with patients’ associations
    • A responsible company
    • Transparency of interests for France
  • The LFB group

    LFB is a pharmaceutical group specialising in plasma derived or recombinant therapeutic proteins for the treatment of serious and often rare diseases.

  • LFB Key dates

    Since the creation of LFB in January 1994, discover the dates that gone down the Group's history.

  • LFB worldwide

    Worldwide, LFB has decided on a targeted strategy

  • A special place in France

    LFB has a special place in France, as a player in the healthcare industry with a public health mission

  • Governance

    A public company active in a competitive market

  • The LFB in pictures

    Discover a series of three videos looking back at the company's transformation over the last few years and unveiling its future objectives.

  • Medicinal products

    15 hospital-prescribed medicinal products

  • LFB Research Grant in Immunology

    LFB confirms its commitment to research for the benefit of patients by launching the second edition, "LFB Research Grant in Immunology."

  • Biosafety

    Patient safety, a top priority for LFB

  • Products under development

    There are several medicinal products at an advanced stage of development, for registration in Europe and the USA

  • Technology platforms

    Two proprietary platforms for therapeutic and technological innovation

  • Improving biosafety

    Innovations to constantly improve the biosafety of medicinal products

  • Rare diseases

    LFB has a continuing commitment to social issues, offering several therapeutic solutions, both currently on sale and under development, for rare diseases

  • Relations with patients’ associations

    LFB is a partner in several patients’ associations and supports projects focused on a better quality of life for patients and their families

  • A responsible company

    LFB’s ethical commitment is reflected in the way it exercises its environmental, social and economic responsibilities

  • Transparency of interests for France

    Transparency of interests for France

Medicinal products
marketed in
40 countries

burger

A pharmaceutical company
specialising
in biological
medicinal products

19 May 2022

2022 LFB corporate Brochure: discover the Denis Delval edito in video

16 May 2022

Discover the new LFB CSR Charter

02 Feb 2022

The new LFB Arras plant in video

15 medicines

prescribed to

hospital

3 fields of therapy
  • Immunology
  • Haemostasis
  • Intensive Care
4

BIOPRODUCTION SITES in the world

2/3

of LFB’s biomedicinal products are intended for the treatment of patients with rare diseases

Group executive committee

Committee’s composition
€ 458 M IN TURNOVER

IN 2021

1 of the leaders in France

IN THE FIELD OF PLASMA-DERIVED MEDICINAL PRODUCTS

19 May 2022

2022 LFB corporate Brochure: discover the Denis Delval edito in video

16 May 2022

Discover the new LFB CSR Charter

02 Feb 2022

The new LFB Arras plant in video

31 Jan 2022

LFB and Kedrion sign an industrial cooperation agreement to supply immunoglobulins in France

28 Oct 2021

Interview with Denis Delval

26 Oct 2021

Bruno de Miribel joins LFB

13 Apr 2021

LFB works for « the France of tomorrow » and unveils a new industrial project in Alès

01 Mar 2021

EMA acceptance for filing of the MARKETING AUTHORISATION application FOR EPTACOG BETA, THE LFB RECOMBINANT FACTOR VIIA , AND PUBLICATION OF THE EXPLORATORY IN VITRO STUDY RESULTS on eptacog beta in combination with emicizumab

All news

3:24

THE NEW LFB ARRAS PLANT, January 2022

3:32

Part 1: three years of LFB transformation

2:38

Part 2 : the new Momentum

3:13

Part 3 : LFB's values

All videos
19 May 2022

2022 LFB corporate Brochure: discover the Denis Delval edito in video

16 May 2022

Discover the new LFB CSR Charter

02 Feb 2022

The new LFB Arras plant in video

31 Jan 2022

LFB and Kedrion sign an industrial cooperation agreement to supply immunoglobulins in France

28 Oct 2021

Interview with Denis Delval

26 Oct 2021

Bruno de Miribel joins LFB

13 Apr 2021

LFB works for « the France of tomorrow » and unveils a new industrial project in Alès

01 Mar 2021

EMA acceptance for filing of the MARKETING AUTHORISATION application FOR EPTACOG BETA, THE LFB RECOMBINANT FACTOR VIIA , AND PUBLICATION OF THE EXPLORATORY IN VITRO STUDY RESULTS on eptacog beta in combination with emicizumab

€ 458 M IN TURNOVER

IN 2021

4

BIOPRODUCTION SITES in the world

1 of the leaders in France

IN THE FIELD OF PLASMA-DERIVED MEDICINAL PRODUCTS

15 medicines

prescribed to

hospital

2/3

of LFB’s biomedicinal products are intended for the treatment of patients with rare diseases

3 fields of therapy
  • Immunology
  • Haemostasis
  • Intensive Care

3:24

THE NEW LFB ARRAS PLANT, January 2022

there is 3 months

3:13

Part 3 : LFB's values

there is 12 months

2:38

Part 2 : the new Momentum

there is 12 months

3:32

Part 1: three years of LFB transformation

there is 1 year

Follow us on

  • The group
    • The LFB group
    • LFB Key dates
    • LFB worldwide
    • A special place in France
      • A player in the healthcare industry
      • A public health mission in france
    • Governance
      • Group Executive Committee
      • LFB BIOMEDICAMENTS
      • LFB BIOTECHNOLOGIES
      • Composition and tasks of the Committees
  • Products and activities
    • LFB Research Grant in Immunology 2021
    • Medicinal products
      • Immunology
      • Haemostasis
      • Intensive care
    • Biosafety
  • Innovation
    • Products under development
    • Technology platforms
      • EMABling®
      • rPRO™ technology
    • Improving biosafety
  • Responsibilities
    • Rare diseases
    • Relations with patients’ associations
    • A responsible company
      • Environmental responsibility
      • Social responsibility
      • Economic responsibility
    • Transparency of interests for France
  • Site map
  • Legal notices
  • Processing of personal data
  • Cookie management policy
  • Cookies management panel
  • Adverse effect reporting
 
 
 

 

×